JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY HYDERABAD B.Pharmacy IV COMPUTER AIDED DRUG DESIGN Previous Question Paper (September - 2022 - R17)

Bioisosterism is a lead modification strategy in medicinal chemistry where functional groups or atoms in a drug molecule are replaced with others that possess similar physical or chemical properties. This substitution aims to improve the biological activity, reduce toxicity, or modify the pharmacokinetic profile of the lead compound while maintaining its essential pharmacological effect.

Bioisosteres are classified into two main categories:

1. Classical Bioisosteres: These involve the replacement of atoms or groups with others that have similar electronic and steric configurations. They are further divided into:
   • Monovalent atoms/groups (e.g., -F, -OH, -NH2, -CH3).
   • Divalent atoms/groups (e.g., -CH2-, -O-, -S-, -NH-).
   • Trivalent atoms/groups (e.g., -CH=, -N=).
   • Ring equivalents (e.g., benzene vs. thiophene).
2. Non-classical Bioisosteres: These do not follow strict steric or electronic rules but mimic the spatial arrangement and electronic distribution required for receptor binding. Examples include replacing a functional group with a cyclic structure, or using a carbonyl group as a surrogate for a sulfonyl group.

Lead discovery based on clinical observation, often referred to as serendipitous drug discovery, involves identifying the therapeutic potential of a compound through unexpected clinical findings or side effects observed during the use of drugs for other indications. This approach has historically been a significant source of novel therapeutic agents.

The process typically follows these stages:

• Observation: Clinicians or researchers notice an unintended beneficial effect of a drug during clinical trials or post-marketing surveillance. A classic example is the discovery of the antihypertensive properties of minoxidil, which was originally investigated for ulcers but caused hypertrichosis (hair growth), leading to its development for alopecia.
• Validation: The observed effect is systematically investigated in controlled preclinical models to confirm that the clinical finding is reproducible and not due to confounding factors.
• Lead Optimization: Once the mechanism of action for the new effect is identified, the chemical structure of the original drug is modified to enhance the new therapeutic activity while minimizing the original (now secondary) activity or other side effects.
• Pharmacological Profiling: The optimized lead undergoes rigorous testing to establish its safety, efficacy, and pharmacokinetic profile for the new therapeutic indication.

This method is highly valuable because the lead compound often already has an established safety profile and human pharmacokinetic data, which significantly accelerates the drug development pipeline compared to de novo discovery.